Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation TCT 2022

Pulmonary to Venous Shunt for Group 2 PH-HFpEF (NXT™ Rivet)

Presenter: Rob Taft

September 17, 2022

Presentation TVT 2022

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Presenter: Sanjiv Shah

June 10, 2022

Presentation THT 2022

Overview of HFpEF Disease State and Physiological Rationale for Atrial Shunting

Presenter: JoAnn Lindenfeld

February 02, 2022

Presentation THT 2022

The Cunundrum of Afib and HFrEF / HFpEF

Presenter: Nassir Marrouche

February 02, 2022

Presentation THT 2022

The Clinical Story of CCM® – Looking ahead to HFpEF Population

Presenter: Javed Butler

February 02, 2022

Presentation THT 2022

The Role of the Neutrophil to Lymphocyte Ratio as a Predictor of Late Gadolinium Enhancement on Cardiac MRI in Patients With HFpEF

Presenter: Amit Jhaveri

February 01, 2022

Presentation THT 2022

How to Treat HFpEF in 2022

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

Molecular Phenotyping

Presenter: Kavita Sharma

February 01, 2022

Presentation THT 2022

Physiological Phenotyping

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

How to Make the Diagnosis

Presenter: Parag Goyal

February 01, 2022

Presentation THT 2022

The Underlying Pathophysiology

Presenter: Greg Lewis

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Presenter: Marat Fudim

February 01, 2022

Presentation THT 2022

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

Presenter: Scott Solomon

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors in HFrEF and HFpEF

Presenter: Stefan Anker

February 01, 2022

Advertisement

Pulmonary to Venous Shunt for Group 2 PH-HFpEF (NXT™ Rivet)

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Overview of HFpEF Disease State and Physiological Rationale for Atrial Shunting

The Cunundrum of Afib and HFrEF / HFpEF

The Clinical Story of CCM® – Looking ahead to HFpEF Population

The Role of the Neutrophil to Lymphocyte Ratio as a Predictor of Late Gadolinium Enhancement on Cardiac MRI in Patients With HFpEF

How to Treat HFpEF in 2022

Molecular Phenotyping

Physiological Phenotyping

How to Make the Diagnosis

The Underlying Pathophysiology

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

SGLT2 Inhibitors in HFrEF and HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content